(Q43281456)

18 November 2017

title

N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands (English)

1 reference

18 November 2017

0 references

1

1 reference

18 November 2017

6

1 reference

18 November 2017

11

1 reference

18 November 2017

12

1 reference

18 November 2017

13

1 reference

18 November 2017

15

1 reference

18 November 2017

Federica Vacondio

2

0 references

Claudia Silva

series ordinal

4

object named as

Claudia Silva

1 reference

18 November 2017

16

Giorgio Tarzia

1 reference

18 November 2017

5

Caterina Carmi

1 reference

18 November 2017

7

Valeria Lucini

1 reference

18 November 2017

8

Marilou Pannacci

1 reference

18 November 2017

10

Francesco Scaglione

1 reference

18 November 2017

Pierfrancesco Orlando

series ordinal

14

object named as

Pierfrancesco Orlando

1 reference

18 November 2017

9

Alessia Caronno

1 reference

18 November 2017

3

Alessandro Fioni

1 reference

18 November 2017

publication date

1 October 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

4

1 reference

18 November 2017

issue

10

1 reference

18 November 2017

page(s)

1746-1755

1 reference

Melatonin: Characteristics, Concerns, and Prospects

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Physiological and metabolic functions of melatonin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin as a hypnotic: pro.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin in Alzheimer's disease and other neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Potential therapeutic use of melatonin in migraine and other headache disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Functional MT1 and MT2 melatonin receptors in mammals

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin as a hypnotic: con.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

The absolute bioavailability of oral melatonin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Ramelteon: a review of its use in insomnia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Major depressive disorder, sleep EEG and agomelatine: an open-label study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Evolution of a Fourth Generation Catalyst for the Amination and Thioetherification of Aryl Halides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Pd-catalyzed amidation of aryl chlorides using monodentate biaryl phosphine ligands: a kinetic, computational, and synthetic investigation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Highly reactive, general and long-lived catalysts for palladium-catalyzed amination of heteroaryl and aryl chlorides, bromides, and iodides: scope and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900240

7 January 2021

Identifiers

DOI

10.1002/CMDC.200900240

1 reference

18 November 2017

1 reference